| CAS NO: | 130929-57-6 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 100mg | 电议 |
| Cas No. | 130929-57-6 |
| 别名 | 恩他卡朋 |
| 化学名 | (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide |
| Canonical SMILES | CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N |
| 分子式 | C14H15N3O5 |
| 分子量 | 305.29 |
| 溶解度 | ≥ 13.1 mg/mL in DMSO, ≥ 12.65 mg/mL in EtOH with ultrasonic |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 文献引用 | |
| 产品描述 | Entacapone is a second-generation catechol-O-methyltransferase (COMT) inhibitor that potently inhibits rat liver total COMT with the half maximal inhibition concentration IC50 and inhibition constant Ki values of 20.1 nM and 10.7 nM respectively. The IC50 values of entacapone against rate liver soluble COMT (S-COMT) and rat liver membrane-bound COMT (MB-COMT) are 14.3 nM and 73.3 nM respectively [1]. Entacapone has succbe used as an adjunct to standard levodopa-dopa decarboxylase inhibitor therapy in patients with Parkinson’s disease (PD), for its abilities to increase the bioavailability of levodopa by inhibiting the generation of 3-O-methyldopa and to prolong the duration and clinical benefit of levodopa [1]. Reference References: |
m.cnreagent.com